In addition to the previously demonstrated superior T cell- and NK cell stimulatory properties and direct tumor cell killing capacity of IL-15 DCs [11, 12, 14], these findings further underscore their strong immunotherapeutic potential as next-generation DC-based vaccines. This evidence concerns the gene IL15 and neoplasm.